Bayer To Settle Monsanto Litigation, Remains Prepared To Invest For Growth
Executive Summary
The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.
You may also be interested in...
Bayer Gives Consumer Health A Star, But Plans $1.76Bn In Annual Overall Cost Reductions
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.
Bayer Consumer Health Recovery Rides Allergy, Dermatology Brand Sales
Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.
Bayer Says $7.6bn Farewell To Animal Health As It Sells Unit To Elanco
Bayer is relinquishing its Animal Health Unit to Elanco as the German major turns its focus more towards life sciences. The money received should help it pay down some Monsanto debt, but there are antitrust concerns.